Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
暂无分享,去创建一个
S. Barni | R. Labianca | G. Beretta | I. Floriani | M. Aglietta | A. Zaniboni | E. Cortesi | L. Isa | S. Lonardi | A. Sobrero | R Labianca | A Sobrero | L Isa | E Cortesi | S Barni | D Nicolella | M Aglietta | S Lonardi | D Corsi | D Turci | G D Beretta | G Fornarini | E Dapretto | I Floriani | A Zaniboni | D. Nicolella | G. Fornarini | D. Turci | D. Corsi | D. Corsi | E. Dapretto | Sara Lonardi | Enrico Cortesi | S. Barni | M. Aglietta | G. D. Beretta | Irene Floriani | Giordano D. Beretta
[1] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[2] R. Labianca,et al. Which 5-fluorouracil regimen?--the great debate. , 1999, Anti-cancer drugs.
[3] J. Crowley,et al. Analyzing survival data from clinical trials and observational studies , 1996 .
[4] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[5] James F. Watkins,et al. Analysing Survival Data from Clinical Trials and Observational Studies. , 1995 .
[6] L. Saltz. Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping? , 2006, Seminars in oncology.
[7] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Grothey,et al. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? , 2006, Clinical colorectal cancer.
[9] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[10] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Grothey,et al. Where do we stand with 5-fluorouracil? , 1999, Seminars in oncology.
[12] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Norman,et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Tournigand,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Herrmann,et al. Does biomodulation of 5-fluorouracil improve results? , 1999, European journal of cancer.
[16] C. Tournigand,et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Barni,et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. , 2009, European journal of cancer.
[18] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[19] M. Valerio,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[21] D. Sargent,et al. End points in advanced colon cancer clinical trials: a review and proposal. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Chu. The role of a drug holiday: even patients with cancer need a vacation. , 2006, Clinical colorectal cancer.
[23] H. Hochster. Stop and go: yes or no? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Kerr,et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial , 2003, The Lancet.